Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children and...
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024. The dividend will ...
Amgen (NASDAQ:AMGN) will present at the 44th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Tuesday, March 5, 2024. Peter Griffith,...
Amgen (NASDAQ:AMGN) today announced the opening of its manufacturing site in Central Ohio, the newest in its global operations network and the most...
Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar...
Amgen (NASDAQ:AMGN) will present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m. ET on Wednesday, Feb. 14, 2024. Jay ...
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2023 versus comparable periods in 2022. "2023 was another...
Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024, after...
Amgen (NASDAQ:AMGN) will present at the 2024 J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Monday, January 8, 2024. Robert A. Bradway,...
Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company's supplemental New Drug...
O SUS deverá fornecer, em breve, um novo tratamento para o Mieloma Múltiplo (MM)1, tipo de câncer hematológico que afeta principalmente pessoas acima ...
Amgen (NASDAQ:AMGN) today announced two changes to its senior leadership team in the areas of research and development (R&D) and technology,...
Amgen (NASDAQ:AMGN) today announced it will serve as the title sponsor of the Irish Open starting in 2024, following the acquisition of Horizon...
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Company's...
Em abril de 2021, em meio à pandemia, Ana Arantes começava uma nova etapa de vida. A mudança de São Paulo (SP) para Florianópolis (SC) era o início...
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the first quarter of 2024. This is the 12th...
Amgen (NASDAQ:AMGN) today announced the presentation of new data from its blood cancer portfolio and pipeline at the 65th American Society of...
Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 9:10 a.m. EST on Wednesday, Nov. 29, 2023. Peter H. Griffith, executive ...
Amgen (NASDAQ:AMGN) today announced new data reinforcing the safety and efficacy of Repatha® (evolocumab) from the FOURIER Open Label Extension (OLE) ...
Amgen (NASDAQ:AMGN) today announced results from the global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early...
Amgen (NASDAQ:AMGN) today announced new data from its Phase 2 study evaluating dazodalibep, an investigational medicine, for the treatment of...
Amgen (NASDAQ:AMGN) today announced new data for KRYSTEXXA® (pegloticase) showing a decrease in blood pressure during treatment of adults living with ...
Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its expanded rheumatology pipeline and portfolio, ...
Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 20231. "We are excited about our pipeline progress and our operating...
Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Tuesday, October 31, 2023, before the opening of the U....
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.